- Home
- ACRS vs PHX Comparison
ACRS vs PHX Comparison
Compare ACRS & PHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- PHX
- Stock Information
- Founded
- ACRS 2012
- PHX 1926
- Country
- ACRS United States
- PHX United States
- Employees
- ACRS N/A
- PHX N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- PHX Oil & Gas Production
- Sector
- ACRS Health Care
- PHX Energy
- Exchange
- ACRS Nasdaq
- PHX Nasdaq
- Market Cap
- ACRS 132.0M
- PHX 148.4M
- IPO Year
- ACRS 2015
- PHX N/A
- Fundamental
- Price
- ACRS $2.24
- PHX $4.14
- Analyst Decision
- ACRS Strong Buy
- PHX Buy
- Analyst Count
- ACRS 5
- PHX 1
- Target Price
- ACRS $11.00
- PHX $4.30
- AVG Volume (30 Days)
- ACRS 656.6K
- PHX 77.4K
- Earning Date
- ACRS 03-04-2025
- PHX 03-11-2025
- Dividend Yield
- ACRS N/A
- PHX 3.87%
- EPS Growth
- ACRS N/A
- PHX N/A
- EPS
- ACRS N/A
- PHX 0.13
- Revenue
- ACRS $27,079,000.00
- PHX $31,939,771.00
- Revenue This Year
- ACRS N/A
- PHX N/A
- Revenue Next Year
- ACRS N/A
- PHX $28.73
- P/E Ratio
- ACRS N/A
- PHX $31.75
- Revenue Growth
- ACRS 26.35
- PHX N/A
- 52 Week Low
- ACRS $0.95
- PHX $2.96
- 52 Week High
- ACRS $5.17
- PHX $4.24
- Technical
- Relative Strength Index (RSI)
- ACRS 39.59
- PHX 58.24
- Support Level
- ACRS $2.11
- PHX $4.00
- Resistance Level
- ACRS $2.42
- PHX $4.20
- Average True Range (ATR)
- ACRS 0.15
- PHX 0.13
- MACD
- ACRS 0.00
- PHX 0.02
- Stochastic Oscillator
- ACRS 26.53
- PHX 81.22
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About PHX PHX Minerals Inc.
PHX Minerals Inc is an oil and natural gas mineral company that has employed a plan to shift the core of its business away from drilling and toward perpetual mineral and natural gas ownership. The company owns substantial mineral acreage, principally in Oklahoma, North Dakota, Texas, New Mexico, and Arkansas, but still maintains legacy interests in natural gas and oil properties that have retired operations. The revenues is derived from royalties granted from the production and sale of natural gas, oil and NGL, and the remaining portion of its revenues is derived from the production and sale of natural gas, oil and NGL on its working interests.